Multiple Myeloma study: JNJ-79635322 vs Teclistamab
Official title A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov ID: NCT07258511
What this study is testing
What is JNJ-79635322?
an investigational subcutaneous injectable medicine being studied as a potential treatment for multiple myeloma
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether JNJ‑79635322 works as well as an anti‑BCMA×CD3 bispecific antibody in people with relapsed or refractory multiple myeloma.
- Who it's for
- You may be able to join if you have multiple myeloma that has come back or did not respond to prior treatment.
- What's involved
- You would receive either JNJ‑79635322 or the other antibody, chosen by chance like a coin toss. You will have regular doctor visits and tests to see how you feel.
- Time commitment
- The study lasts several months with visits every few weeks.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria
- Measurable disease at screening as assessed by central laboratory
- Received at least 3 prior lines of antimyeloma therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-cluster of...
- Documented evidence of progressive disease (PD) or failure to achieve a response to the last line of therapy based on investigator's determination of...
- Toxicity related to previous anticancer therapy must have resolved to Grade 1 or better
See the full eligibility criteria
- MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria
- Measurable disease at screening as assessed by central laboratory
- Received at least 3 prior lines of antimyeloma therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-cluster of differentiation (CD)38 antibody
- Documented evidence of progressive disease (PD) or failure to achieve a response to the last line of therapy based on investigator's determination of response by IMWG criteria
- Toxicity related to previous anticancer therapy must have resolved to Grade 1 or better
- Active hepatitis of infectious origin
- Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM
- Suspected or known allergies, hypersensitivity, or intolerance to the excipients of JNJ-79635322 and Teclistamab
- Major surgery, (example, requiring general anesthesia) within 2 weeks before first dose, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate...
- Received or plans to receive any live, attenuated vaccine within 4 weeks before the first dose of study treatment, or during study treatment
The study team makes the final eligibility decision.
Where it is enrolling
- Phoenix, Arizona, United States
- Little Rock, Arkansas, United States
- Duarte, California, United States
- Irvine, California, United States
- Los Angeles, California, United States
- San Francisco, California, United States
- Denver, Colorado, United States
- Farmington, Connecticut, United States
- New Haven, Connecticut, United States
- Fort Myers, Florida, United States
- Jacksonville, Florida, United States
- Miami, Florida, United States
- Tampa, Florida, United States
- Atlanta, Georgia, United States
- Zion, Illinois, United States
- Iowa City, Iowa, United States
- Waukee, Iowa, United States
- Kansas City, Kansas, United States
- Louisville, Kentucky, United States
- Baltimore, Maryland, United States
+ 116 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Phoenix, Arizona, United States; Little Rock, Arkansas, United States; Duarte, California, United States; Irvine, California, United States; Los Angeles, California, United States; San Francisco, California, United States and 130 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.